/
Oncology
Pancreatic Ductal Adenocarcinoma
120
Pipeline Programs↗
119
Active Trials↗
70
Companies Involved↗
Pancreatic Ductal Adenocarcinoma is a highly competitive landscape with 120 programs across 70 companies. The most active players are Boehringer Ingelheim, Perspective Therapeutics, Novartis. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 141
Phase 251
Phase 313
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
87 of 107 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 90% of 120 pipeline programs.
Analysis
Trial Status
175
clinical trials
Recruiting68 · 39%
Not yet recruiting28 · 16%
Completed27 · 15%
Active, not recruiting22 · 13%
Terminated16 · 9%
Unknown status5 · 3%
Other9 · 5%
Clinical Trials
Trial Activity
175 trials
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)